

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 August 2018 (30.08.2018)



(10) International Publication Number
WO 2018/154390 A1

(51) International Patent Classification:
C07K 16/18 (2006.01) **C07K 16/44** (2006.01)

(21) International Application Number:
PCT/IB2018/000249

(22) International Filing Date:
27 February 2018 (27.02.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
JP 2017-035594 27 February 2017 (27.02.2017) JP

(71) Applicants: **TEIJIN PHARMA LIMITED** [JP/JP]; 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). **MURAKAMI, Takashi**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). **MERCK SHARP & DOHME CORP.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors: **EGUCHI, Hiroshi**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). **MURAKAMI, Takashi**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). **NAMIKI, Naoko**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). **TANOKURA, Akira**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). **BAKER, Jeanne, E.**; c/o Merck Sharp & Dohme Corp., 901 S. California Avenue, Palo Alto, CA 94304 (US). **PARMENTIER BATTEUR, Sophie**; c/o Merck Sharp & Dohme Corp., 770 Sumneytown Pike, West Point, PA 19486 (US). **JABLONSKI, Angela, Marie**; c/o Merck Sharp & Dohme Corp., 770 Sumneytown Pike, West Point, PA 19486 (US). **MALASHOCK, Daniel, Stephen**; c/o Merck Sharp & Dohme Corp., 901 S. California Avenue, Palo Alto, CA 94304 (US). **MIECZKOWSKI, Carl**; c/o Merck Sharp & Dohme Corp., 901 S. California Avenue, Palo Alto, CA 94304 (US). **RAGHUNATHAN, Gopalan (raghu)**; c/o Merck Sharp & Dohme Corp., 901 S. California Avenue, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME

(57) Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.

WO 2018/154390 A1